Cancer has emerged as one of the leading cause of deaths worldwide. A three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis was performed on a series of quinazoline-based anticancer agents. Purpose of the study is to understand the structural basis for their inhibitory activity. Comparative molecular field analysis (CoMFA) technique was employed to develop 3D-QSAR model. Ligand-based alignment scheme was used to generate a reliable CoMFA model. The model produced statistically significant results with a cross-validated correlation coefficient (q 2 ) of 0.589 and a non-cross-validated correlation coefficient (r 2 ) of 0.928. Model was further validated by bootstrapping and progressive scrambling analysis. This study could assist in the design of novel and more potent anticancer agents.
Introduction
Cancer is among the leading cause of death worldwide [1] . The number of deaths due to cancer is expected to reach approximately 13.1 million by 2030. Many bioactive compounds have been reported to possess anticancer activity [2] . However, their use as anticancer agents is limited because of the side effects or the limited scope. Hence, the identification of novel, potent drugs with a broad spectrum of activity and fewer side effects is required for the improvement of cancer treatment. Antimitotic agents which interact with microtubules are widely used in the cancer chemotherapy [3] [4] [5] [6] [7] . Microtubules or tubulin protein polymers are a major component of the cytoskeleton of eukaryotic cells. Tubulin proteins can polymerize as well as depolymerize, and microtubules can undergo rapid cycles of assembly and disassembly. Antimitotic agents interact with tubulin either at the colchicine-, vinblastine-or paclitaxel-binding site [8] . These agents either inhibit or promote microtubule polymerization and accordingly affect their function.
Tremendous efforts have been made to develop anticancer agents and a number of antimitotic compounds have been synthesized as promising drug candidates [9] .
Recently, quinazoline-based anticancer agents were reported [10] . However, a three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis on these inhibitors has not been performed to establish exactly how their chemical structures relate to the inhibitory activities. Our research group is involved in molecular modeling studies [11] [12] [13] [14] [15] . Here, we have performed comparative molecular field analysis (CoMFA) to identify the key structural elements that are required in the rational design of novel drug candidates.
Experimental Section

Data Set
A data set of 45 quinazoline-based anticancer agents was collected [10] . Reported activity values (IC 50 ) of inhibitors were converted into pIC 50 values for 3D-QSAR analysis. Converted pIC 50 values were used as the dependent variables for developing CoMFA model. The energy minimized structure of the most active compound (28) was used as template to construct other compounds of the data set. All 3D structures were sketched using SYBYL-X2.0 [16] . Gasteiger-Hückel partial atomic charges were applied to the structures. Energy minimization was performed using Tripos force field. The minimized structures were aligned to the template molecule using common substructure-based alignment method. Chemical structures and biological activities of the compounds are given in Table 1 .
CoMFA
CoMFA calculations were performed using SYBYL-X2.0. CoMFA technique is based on the assumption that variations in the activity of compounds are related to the changes in the steric and electrostatic fields [17] . CoMFA steric (Lennard-Jones potential) and electrostatic (Coulomb potential) interaction fields were calculated using default settings. A 3D cubic lattice with a grid spacing of 2.0 Å was created and fields were generated using a sp 3 carbon probe atom carrying +1 charge and van der Waals radius of 1.50 Å. An energy cut-off of 30 kcal mol -1 was used for the calculation of interaction fields. Relationship between structural parameters and biological activities was derived using Partial least squares (PLS) regression algorithm [18] . CoMFA descriptors were used as independent variables while pIC 50 values were used as dependent variables in the PLS analysis. The leave-one-out (LOO) cross-validation was carried out to obtain cross-validated correlation coefficient (q 2 ), optimal number of components (NOC) and standard error of prediction (SEP). The non-cross-validated analysis was performed to obtain non-cross-validated correlation coefficient (r 2 ), standard error of estimate (SEE) and F-test value (F). Developed CoMFA model was validated using bootstrapping analysis [19] and progressive scrambling. Bootstrapping of 100 runs and a total of 100 independent scramblings with a maximum of 10 bins and a minimum of 2 bins were carried out.
Results and Discussion
CoMFA Model
CoMFA model was developed using a series of quinazoline-based anticancer agents. Model was generated from the whole data set using ligand-based alignment scheme. All data set compounds were aligned over the template (compound 28) using common substructure alignment method. The aligned compounds are displayed in Fig. 1 Table 3 . The scatter plot for actual versus predicted pIC 50 values is shown in Fig. 2 . Predicted activities are in agreement with the experimental values suggesting that a reliable CoMFA model was developed.
CoMFA Contour Maps
The CoMFA results were graphically interpreted by the field contribution maps. The contour maps of different fields are displayed with template (compound 28). Maps describe default 80% and 20% level contributions for favorable and unfavorable regions, respec- tively. Maps indicate spatial requirement of steric and electrostatic fields for improving the inhibitory activity of the compounds. Steric contour map is displayed in Fig. 3 . Green contours indicate favorable regions whereas yellow contours indicate unfavorable regions for bulky group substitution. A green contours observed near R 3 substitution suggested that bulky groups in this region are favorable for increasing the activity. This could be the possible reason for better inhibitory activities of compounds 25, 27, 28 and 30 as compared to compound 1. Yellow contours observed around R 1 substitution sug- gested that small groups are favored in this region and bulky substituents could decrease the activity. This might be the possible reason for the lower activities of compounds 2, 3 and 5 as compared to compounds 6, 16 and 17. Electrostatic contour map is displayed in Fig. 4 . Blue contours indicate regions where electropositive substitutions are favored while red contours indicate favorable regions for electronegative substitutions to enhance the activity. Blue contours observed near R 1 substitution suggested that electropositive groups at that position could increase the activity. This could be the possible reason for higher activities of compounds 15, 16 and 17 than compounds 2 and 3. The red contour observed near R 2 substitution suggested that electronegative groups at that position could improve the activity. This might be the reason for higher activity of compound 22 than compounds 20 and 23.
Conclusions
In the present study, a CoMFA model was developed for a series of quinazoline-based anticancer agents. The model provided some insights into the crucial structural factors affecting the bioactivity of these anticancer agents. Ligand-based alignment scheme and GasteigerHückel partial charges produced a reliable CoMFA model. The model showed statistically acceptable results in terms of q 2 and r 2 values. Validation results of bootstrapping and progressive sampling also indicated that the developed model is robust. Contour map analysis highlighted regions for chemical modification to improve the inhibitory activity of the compounds. Smaller groups with electropositive properties at R 1 substitution whereas electronegative groups at R 2 substitution and bulky groups at R 3 substitution are desirable to improve the inhibitory potency. These results may provide some useful and rational suggestions for the design of novel and more potent anticancer agents.
